| __timestamp | MorphoSys AG | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 77000 | 520990000000 |
| Thursday, January 1, 2015 | 77000 | 535405000000 |
| Friday, January 1, 2016 | 97000 | 558755000000 |
| Sunday, January 1, 2017 | 33000 | 495921000000 |
| Monday, January 1, 2018 | 1796629 | 659690000000 |
| Tuesday, January 1, 2019 | 12085198 | 1089764000000 |
| Wednesday, January 1, 2020 | 9174146 | 994308000000 |
| Friday, January 1, 2021 | 32200000 | 1106846000000 |
| Saturday, January 1, 2022 | 48620000 | 1244072000000 |
| Sunday, January 1, 2023 | 58355000 | 1431505000000 |
| Monday, January 1, 2024 | 1431505000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for strategic planning. This analysis delves into the cost of revenue for Takeda Pharmaceutical Company Limited and MorphoSys AG from 2014 to 2023. Takeda, a global leader, consistently shows a robust cost of revenue, peaking at approximately 1.43 trillion in 2023, reflecting a 174% increase since 2014. In contrast, MorphoSys AG, a smaller biotech firm, exhibits a more volatile trend, with costs rising from a modest 77,000 in 2014 to 58 million in 2023, marking a staggering 75,000% increase. This disparity highlights the scale and operational differences between the two companies. Notably, the data for 2024 is incomplete, indicating potential shifts in the coming years. Such insights are invaluable for investors and stakeholders aiming to navigate the complexities of the pharmaceutical sector.
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs Takeda Pharmaceutical Company Limited
Analyzing Cost of Revenue: GSK plc and MorphoSys AG
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Mesoblast Limited
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Xencor, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs MorphoSys AG
Cost of Revenue Trends: Perrigo Company plc vs MorphoSys AG
Cost of Revenue Comparison: MorphoSys AG vs Taro Pharmaceutical Industries Ltd.
Comparing Cost of Revenue Efficiency: MorphoSys AG vs MiMedx Group, Inc.